• Mashup Score: 10
    A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements - 1 year(s) ago

    Theranostics is the combination of two approaches—diagnostics and therapeutics—applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu–prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent potential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radionuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field. Keywords: Molec

    Source: pubs.rsna.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      RT @radiolobt: A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements https://t.co/iJJCgecaRv 🔵Very nice…

  • Mashup Score: 4
    Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization? - European Radiology - 1 year(s) ago

    Objectives To evaluate MRI diagnostic performance in detecting clinically significant prostate cancer (csPCa) in peripheral-zone PI-RADS 4 lesions, comparing those with clearly restricted diffusion (DWI-score 4), and those with equivocal diffusion pattern (DWI-score 3) and positive dynamic contrast-enhanced (DCE) MRI. Methods This observational prospective study enrolled 389 men referred to MRI…

    Source: SpringerLink
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      https://t.co/OZMygpHHV7 Categorizing PI-RADS 3 lesions in PI-RADS 3 and “3up” (enhancement) dilutes PI-RADS 4. Thus, only men with elevated PSAD or other risk factors should undergo biopsy. Further validation is needed. The EAU-guideline-table may help what to do in PI-RADS 3. https://t.co/uNB4RL1cBo

  • Mashup Score: 0
    Kanker.nl - we zijn er voor je | Kanker.nl - 2 year(s) ago

    Kanker.nl is de plek voor betrouwbare informatie en ervaringen van anderen. Stel je vraag over kanker, ontmoet lotgenoten of schrijf je eigen blog. We zijn er voor je.

    Source: Kanker.nl
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      RT @BigChallenges: @JelleBarentsz geeft antwoord op vragen op https://t.co/qvogzOvYZx https://t.co/BWOwT5JXot

  • Mashup Score: 1
    Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit - 2 year(s) ago

    Informed choice approaches lead to high rates of unsystematic PSA testing, especially among those least likely to benefit and most likely to be harmed, argue Andrew Vickers and colleagues Screening for prostate cancer with prostate specific antigen (PSA) remains highly controversial because it is unclear whether the benefits of reduced prostate cancer mortality offset the harms of overdiagnosis…

    Source: The BMJ
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      1/1 @VickersBiostats: https://t.co/6qUv5ovwPZ “Opportunistic screening for prostate cancer provides limited reduction in cancer-specific deaths.” Read more #CancerScreening #PSATesting #ProstateCancer #MRI What are the reasons? See 2/2.

  • Mashup Score: 0
    jellebarentsz.com - 2 year(s) ago

    +31625015262 / jellebarentsz@gmail.com Welcome to my site! My name is Jelle Barentsz my hobby is photography My profession is Radiology, and I like to see “sharp” pictures.This is why I try to make the photos I take as sharp as possible. Please look at my site and enjoy!

    Source: jellebarentsz.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      Thank you Leo. You are now yourself a true prostate MRI leader with excellence in education and patient care. I am happy to be your friend! You opened my love for Brazil and the rainforest. That is a place we must preserve. I have a few pictures on my site https://t.co/F6fgdvF0Qw https://t.co/3WeyeJktLN

  • Mashup Score: 0
    Prostate Imaging Workshop - 2 year(s) ago

    The three-day workshop will include the following: • Prostate MRI Theory • Prostate Anatomy • PI-RADS • mpMRI Prostate • PSMA PET/CT Scan • Prostate PET/MRI fusion • Prostate biopsies techniques • Prostate cancer treatment options with special guest speakers to present on the leading radiation oncology and surgical treatment options, whilst ensuring a focus on how the radiology report can assist…

    Source: www.trybooking.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JelleBarentsz
      JelleBarentsz

      Join us in Sydney, see: https://t.co/yp9n46u3mh https://t.co/dZw5blQvUa

Load More